Stocks and Investing Stocks and Investing
Mon, October 31, 2022

Frank Morgan Maintained (AMED) at Buy with Decreased Target to $139 on, Oct 31st, 2022


Published on 2024-10-27 23:47:01 - WOPRAI, Frank Morgan
  Print publication without navigation


Frank Morgan of RBC Capital, Maintained "Amedisys, Inc." (AMED) at Buy with Decreased Target from $165 to $139 on, Oct 31st, 2022.

Frank has made no other calls on AMED in the last 4 months.



There are 8 other peers that have a rating on AMED. Out of the 8 peers that are also analyzing AMED, 2 agree with Frank's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Scott Fidel of "Stephens & Co." Maintained at Hold with Decreased Target to $105 on, Friday, October 28th, 2022
  • John Ransom of "Raymond James" Downgraded from Buy to Hold on, Thursday, October 27th, 2022


These are the ratings of the 6 analyists that currently disagree with Frank


  • David Macdonald of "Truist Securities" Maintained at Strong Buy with Decreased Target to $130 on, Friday, October 28th, 2022
  • Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $145 on, Friday, October 28th, 2022
  • Sarah James of "Barclays" Maintained at Buy with Decreased Target to $126 on, Friday, October 28th, 2022
  • Justin Bowers of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $165 on, Monday, October 24th, 2022
  • Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $135 on, Monday, October 3rd, 2022
  • Andrew Mok of "UBS" Downgraded from Hold to Strong Sell and Decreased Target to $95 on, Tuesday, August 2nd, 2022
Contributing Sources